Sclerostin单克隆抗体治疗骨质疏松的研究进展

Research progress on the effect of sclerostin monoclonal antibody in treating osteoporosis

硬骨素(Sclerostin)是由硬化性骨病(sclerosteosis,SOST)基因编码的蛋白质,可以通过与低密度脂蛋白受体相关蛋白5/6(low density lipoprotein receptor-related protein,LRP5/6)结合达到拮抗Wnt蛋白并抑制成骨的作用,已经作为新的药物靶点用于抗骨质疏松药物研发。目前,围绕Sclerostin单克隆抗体已经进行了许多基础研究和临床研究,结果提示该类药物可以提高骨量、促进骨形成、抑制骨吸收,对于骨质疏松有一定治疗效果。但该类药物应用后的副反应,对骨折的影响等方面的研究数据尚不足,有待完善进一步研究。

Sclerostin,a protein encoded by sclerosteosis（ SOST） gene,antagonizes the Wnt protein via the low density lipoprotein receptor-related protein（ LRP5/6） receptor and inhibits bone formation. It has been a new target for the treatment of osteoporosis.Both basic and clinical researches have indicated that sclerostin monoclonal antibody can treat osteoporosis by increasing bone mineral density,promoting bone formation and inhibiting bone resorption. However,limited data have evaluated the adverse effects of sclerostin monoclonal antibody and its influence on bone fracture,which deserve further studies.